Overview of melanoma vaccines and promising approaches

Monica C. Panelli, Ena Wang, Vladia Monsurrò, Ping Jin, Zavaglia Katia, Kina Smith, Yvonne Ngalame, Francesco M. Marincola

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

It is difficult to envision anything better than melanoma vaccines to exemplify the effectiveness of modern biotechnology in developing biologically rational therapeutics. Melanoma vaccines can reproducibly induce cytotoxic T lymphocyte (CTL) responses better than any other anticancer therapy. Anticancer vaccines have been labeled by some as ineffective for the simple reason that they only rarely lead to cancer regression. This oxymoron stems from the naïve expectation that CTLs are all that is needed to reject cancer. Little is known about requirements for CTL localization and effector function within the tumor microenvironment. In the future, more attention should be given to events downstream of immunization (afferent arm of immune response) to identify combination therapies likely to facilitate localization and activation of CTL at the receiving end (efferent arm).

Original languageEnglish
Pages (from-to)414-420
Number of pages7
JournalCurrent Oncology Reports
Volume6
Issue number5
Publication statusPublished - Sep 2004
Externally publishedYes

Fingerprint

Cytotoxic T-Lymphocytes
Melanoma
Vaccines
Tumor Microenvironment
Biotechnology
Immunization
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Panelli, M. C., Wang, E., Monsurrò, V., Jin, P., Katia, Z., Smith, K., ... Marincola, F. M. (2004). Overview of melanoma vaccines and promising approaches. Current Oncology Reports, 6(5), 414-420.

Overview of melanoma vaccines and promising approaches. / Panelli, Monica C.; Wang, Ena; Monsurrò, Vladia; Jin, Ping; Katia, Zavaglia; Smith, Kina; Ngalame, Yvonne; Marincola, Francesco M.

In: Current Oncology Reports, Vol. 6, No. 5, 09.2004, p. 414-420.

Research output: Contribution to journalReview article

Panelli, MC, Wang, E, Monsurrò, V, Jin, P, Katia, Z, Smith, K, Ngalame, Y & Marincola, FM 2004, 'Overview of melanoma vaccines and promising approaches', Current Oncology Reports, vol. 6, no. 5, pp. 414-420.
Panelli MC, Wang E, Monsurrò V, Jin P, Katia Z, Smith K et al. Overview of melanoma vaccines and promising approaches. Current Oncology Reports. 2004 Sep;6(5):414-420.
Panelli, Monica C. ; Wang, Ena ; Monsurrò, Vladia ; Jin, Ping ; Katia, Zavaglia ; Smith, Kina ; Ngalame, Yvonne ; Marincola, Francesco M. / Overview of melanoma vaccines and promising approaches. In: Current Oncology Reports. 2004 ; Vol. 6, No. 5. pp. 414-420.
@article{642f8bcb3a204f00b9bac951f461b8ac,
title = "Overview of melanoma vaccines and promising approaches",
abstract = "It is difficult to envision anything better than melanoma vaccines to exemplify the effectiveness of modern biotechnology in developing biologically rational therapeutics. Melanoma vaccines can reproducibly induce cytotoxic T lymphocyte (CTL) responses better than any other anticancer therapy. Anticancer vaccines have been labeled by some as ineffective for the simple reason that they only rarely lead to cancer regression. This oxymoron stems from the na{\"i}ve expectation that CTLs are all that is needed to reject cancer. Little is known about requirements for CTL localization and effector function within the tumor microenvironment. In the future, more attention should be given to events downstream of immunization (afferent arm of immune response) to identify combination therapies likely to facilitate localization and activation of CTL at the receiving end (efferent arm).",
author = "Panelli, {Monica C.} and Ena Wang and Vladia Monsurr{\`o} and Ping Jin and Zavaglia Katia and Kina Smith and Yvonne Ngalame and Marincola, {Francesco M.}",
year = "2004",
month = "9",
language = "English",
volume = "6",
pages = "414--420",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "5",

}

TY - JOUR

T1 - Overview of melanoma vaccines and promising approaches

AU - Panelli, Monica C.

AU - Wang, Ena

AU - Monsurrò, Vladia

AU - Jin, Ping

AU - Katia, Zavaglia

AU - Smith, Kina

AU - Ngalame, Yvonne

AU - Marincola, Francesco M.

PY - 2004/9

Y1 - 2004/9

N2 - It is difficult to envision anything better than melanoma vaccines to exemplify the effectiveness of modern biotechnology in developing biologically rational therapeutics. Melanoma vaccines can reproducibly induce cytotoxic T lymphocyte (CTL) responses better than any other anticancer therapy. Anticancer vaccines have been labeled by some as ineffective for the simple reason that they only rarely lead to cancer regression. This oxymoron stems from the naïve expectation that CTLs are all that is needed to reject cancer. Little is known about requirements for CTL localization and effector function within the tumor microenvironment. In the future, more attention should be given to events downstream of immunization (afferent arm of immune response) to identify combination therapies likely to facilitate localization and activation of CTL at the receiving end (efferent arm).

AB - It is difficult to envision anything better than melanoma vaccines to exemplify the effectiveness of modern biotechnology in developing biologically rational therapeutics. Melanoma vaccines can reproducibly induce cytotoxic T lymphocyte (CTL) responses better than any other anticancer therapy. Anticancer vaccines have been labeled by some as ineffective for the simple reason that they only rarely lead to cancer regression. This oxymoron stems from the naïve expectation that CTLs are all that is needed to reject cancer. Little is known about requirements for CTL localization and effector function within the tumor microenvironment. In the future, more attention should be given to events downstream of immunization (afferent arm of immune response) to identify combination therapies likely to facilitate localization and activation of CTL at the receiving end (efferent arm).

UR - http://www.scopus.com/inward/record.url?scp=4544291831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544291831&partnerID=8YFLogxK

M3 - Review article

VL - 6

SP - 414

EP - 420

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 5

ER -